checkmate 274: nivolumab versus placebo in high-risk urothelial cancer
Published 3 years ago • 171 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
1:35
checkmate 274: adjuvant nivolumab versus placebo for urothelial carcinoma
-
4:22
checkmate 274 & ev-301: highlights in uc from asco gu
-
2:19
checkmate 274: biomarkers linked to disease-free survival with adjuvant nivolumab
-
2:13
adjuvant nivolumab as soc for high-risk muscle-invasive urothelial carcinoma after radical resection
-
12:12
checkmate 274 adjuvant nivolumab in urothelial cancer | an oncologist's take
-
5:19
harmoni-02 comparing ivonescimab vs. pembrolizumab in patients with mnsclc
-
55:18
lecture on cancer [ coffee/ cancer; ev pembro; censoring] to ucsf fresno
-
15:49
9 signs in liver cancer 😱❌
-
2:22
adjuvant nivolumab in patents with high-risk resected melanoma
-
2:53
matthew galsky, md, elaborates on outcomes from the checkmate 274 trial
-
4:14
adjuvant nivolumab in patients with resected esophageal or gej cancer (checkmate 577)
-
3:39
checkmate 7fl: nivo vs pbo in high-risk er her2- bc with neoadjuvant chemo and adjuvant therapy
-
3:12
nivolumab for perioperative esophageal and gastroesophageal cancer: checkmate 577
-
3:43
checkmate 274: estimating the underlying cure fraction for patients with high-risk miuc
-
2:09
checkmate 032: nivolumab/ipilimumab for urothelial carcinoma
-
4:45
highlights in kidney and bladder cancer at asco gu 2021
-
5:44
4-year results from checkmate 238: adjuvant nivo vs ipi in resected stage iii/iv melanoma
-
1:59
checkmate 238: nivolumab versus ipilimumab in stage iii melanoma
-
5:22
checkmate 743: first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...
-
1:28
immune checkpoint inhibitors and sitravatinib in bladder cancer
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
2:48
checkmate067 outcomes: nivolumab plus ipilimumab in advanced melanoma